Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
145 participants
OBSERVATIONAL
2023-06-19
2025-08-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection
NCT05831189
Treatment of Recurrent Clostridium Difficile Infection With RBX7455
NCT02981316
C. Difficile Toxin Levels in Stool From Healthy Individuals Following Standard of Care Antibiotic Treatment for CDI.
NCT07250724
Lyophilized Fecal Microbiota Transplantation for Recurrent Clostridioides Difficile Infection
NCT03834038
SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)
NCT02437487
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
REBYOTA™
REBYOTA™
REBYOTA™ is administered in the rectum
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
REBYOTA™
REBYOTA™ is administered in the rectum
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥ 18 years
* Diagnosis of rCDI as determined by the treating physician
* Completed antibiotic treatment for the presenting rCDI episode
* Prescription for REBYOTA™ to prevent rCDI according to the approved indication
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ferring Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Global Clinical Compliance
Role: STUDY_DIRECTOR
Ferring Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ferring Investigational Site
Chandler, Arizona, United States
Ferring Investigational Site
Chula Vista, California, United States
Ferring Investigational Site
Murrieta, California, United States
Ferring Investigational Site
Oceanside, California, United States
Ferring Investigational Site
Sacramento, California, United States
Ferring Investigational Site
Hamden, Connecticut, United States
Ferring Investigational Site
Gainesville, Florida, United States
Ferring Investigational Site
Orlando, Florida, United States
Ferring Investigational Site
Port Orange, Florida, United States
Ferring Investigational Site
Tampa, Florida, United States
Ferring Investigational Site
Zephyrhills, Florida, United States
Ferrin Investigational Site
Atlanta, Georgia, United States
Ferring Investigational Site
La Grange, Georgia, United States
Ferring Investigational Site
Savannah, Georgia, United States
Ferring Investigational Site
Burr Ridge, Illinois, United States
Ferring Investigational Site
Maywood, Illinois, United States
Ferring Investigational Site
Iowa City, Iowa, United States
Ferring Investigational Site
Wichita, Kansas, United States
Ferring Investigational Site
Jefferson, Louisiana, United States
Ferring Investigational Site
Boston, Massachusetts, United States
Ferring Investigational Site
Worcester, Massachusetts, United States
Ferring Investigational Site
Detroit, Michigan, United States
Ferring Investigational Site
Detroit, Michigan, United States
Ferring Investigational Site
Farmington Hills, Michigan, United States
Ferring Investigational Site
Omaha, Nebraska, United States
Ferring Investigational Site
Teaneck, New Jersey, United States
Ferring Investigational Site
New York, New York, United States
Ferring Investigational Site
New York, New York, United States
Ferring Investigational Site
New York, New York, United States
Ferring Investigational Site
Rochester, New York, United States
Ferring Investigational Site
Stony Brook, New York, United States
Ferring Investigational Site
Fargo, North Dakota, United States
Ferring Investigational Site
Cincinnati, Ohio, United States
Ferring Investigational Site
Middleburg Heights, Ohio, United States
Ferring Investigational Site
DuBois, Pennsylvania, United States
Ferring Investigational Site
Pittsburgh, Pennsylvania, United States
Ferring Investigational Site
Charleston, South Carolina, United States
Ferring Investigational Site
Knoxville, Tennessee, United States
Ferring Investigational Site
Dallas, Texas, United States
Ferring Investigational Site
Houston, Texas, United States
Ferring Investigational Site
West Jordan, Utah, United States
Ferring Investigational Site
Charlottesville, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
000422
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.